Effectiveness, safety and tolerability of Ozenoxacin 2% lotion vs Clindamycin 1% lotion in mild to moderate truncal acne: An open label randomized controlled clinical trial

Clicks: 15
ID: 326871
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #38 of 188 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 188 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Truncal acne is a frequently encountered but relatively understudied manifestation of acne vulgaris and is often associated with significant physical discomfort and psychosocial impact. Topical clindamycin has been extensively used in mild to moderate acne, however, there are concerns regarding antimicrobial resistance which has prompted interest in alternative topical agents. Ozenoxacin, a non-fluorinated quinolone, offers broad-spectrum antibacterial activity with minimal systemic absorption. OBJECTIVES: To compare the effectiveness, safety, and tolerability of ozenoxacin 2% lotion with clindamycin 1% lotion in patients with mild to moderate truncal acne. METHODS: This institution-based, open-label, randomized controlled trial included 78 patients aged 18-35 years with mild to moderate truncal acne. Participants were randomized to receive either ozenoxacin 2% lotion or clindamycin 1% lotion applied twice daily for 12 weeks. Both groups received adapalene 0.1% gel once daily at bedtime. Clinical efficacy was assessed using Investigator Global Assessment (IGA), total lesion count, inflammatory and non-inflammatory lesion counts, Cardiff Acne Disability Index (CADI), and Dermatology Life Quality Index (DLQI). Safety was evaluated through adverse event monitoring. RESULTS: Thirty-five patients in the ozenoxacin group and thirty-four in the clindamycin group completed the study. Both groups demonstrated statistically significant improvement from baseline in all efficacy parameters at 12 weeks (p < 0.05). Intergroup comparisons showed no statistically significant differences across clinical or quality-of-life outcomes. Both treatments were well tolerated, with only mild and transient adverse effects reported. CONCLUSION: Ozenoxacin demonstrated comparable efficacy and tolerability to clindamycin when used in combination with adapalene, in truncal acne.
Reference Key
openalex_W7204260763 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anupam Das, Sambit Chatterjee, Saikat Banerjee, Sujata Sengupta
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag372
URL
https://doi.org/10.1093/ced/llag372
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.